ebe-efpia initiative escher-atmp project results · escher-atmp project ebe-efpia initiative:...
TRANSCRIPT
![Page 1: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/1.jpg)
EBE-EFPIA Initiative
Escher-ATMP Project ResultsRenske ten Ham, MSc
Division of Pharmacoepidemiology and Clinical Pharmacology - Utrecht University
![Page 2: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/2.jpg)
Escher-ATMP Project
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
OverallAim:ExaminefactorsassociatedwithsuccessfulATMPdevelopmentandcommercialisationin Europe.
Workpackage1
Survey:Provideoverviewofproductanddevelopercharacteristicsandidentifyexperiencedchallenges.
Workpackage2
Interviews:SubstantiatetheobservedfindingsfromWP1byidentifyingchallengeroot-causes.
![Page 3: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/3.jpg)
ATMP Landscape in Europe
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
271 DevelopersIdentified38% SurveyResponse
ATMPType
46% 53%
1%
40%
59%
1%
GeneTherapy CellbasedTherapy
CombATMP
Fullcohort
Respondents
In201665%of
developersareSMEs,35%arelargedevelopers.
![Page 4: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/4.jpg)
ATMP Landscape in Europe
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
271 DevelopersIdentified38% SurveyResponse
DeveloperDevelopmentStage
In201665%of
developersareSMEs,35%arelargedevelopers.
41
106 7
EarlyClinicalStage(phase
I-II)
LateClinicalStage(phase
III)
RegulatoryApprovalAppl
ProductCom
![Page 5: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/5.jpg)
Survey Results
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
ExperiencedChallenges– Grouped
0%
25%
50%
75%
100% Otherchallenge(s)
HRMchallenge(s)
Clinicalchallenge(s)
Financialchallenge(s)
Scientificchallenge(s)
Technicalchallenge(s)
Regulatorychallenge(s)
Top5ExperiencedChallenges
MeetingCountrySpecificRequirements
ProductManufacturing
ClinicalTrialDesign
MAADossierContentUncertainty
QualityStandards
16%
6%
15%
8%
5%
1
2
3
4
5MAA=MarketAuthorisationApplication
![Page 6: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/6.jpg)
Survey Results - Quotes
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
“IMPDneededresearchlevel(…)becauselegislationwasnewandnobodyhadacluehowto
doanimaltesting”
“Conductingregulatoryroadshowtomeetwithregulatorybodiesto
understandrequirementsandobtainalignment”
“LackofGMPgraderawmaterials”
“SlowCTAandGMOassessment”
“Findingappropriateclinicalinvestigationsites”
“Forregulatoryacceptancereasonstheearlystageclinicaltargetgroupwithinthepatientpopulationdiffersfromthefinalpatienttargetgroup”
![Page 7: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/7.jpg)
Combining Survey Results with Interviews
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
ManydifferentchallengingandfacilitatingfactorsidentifiedincommercialEUATMPdevelopment.Twoelementscausingmanyhurdlesare:
ThedisconnectbetweenEuropean(highlevel)regulationandnationalhurdles.
CapabilitiesandbusinessmodelatthestarthaveeffectthroughoutATMPdevelopmentsuccess.
![Page 8: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/8.jpg)
Disconnect between European (high level) regulation and national hurdles
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
CommercialdevelopersfindEuropeaneffortssofarhelpedATMPdevelopmentmoveforward.However,localinterpretationandexecutionleadstomanyadditional(duplicate)informationrequests,delaysandincreasedcost.
Smallcompaniesdonothavetheresourcestoaddresscountryspecificrequirements.Also,highdatarequestburdendrivespreferenceofglobaldeveloperstolaunchfirstinUSorAsia.
NationalAuthoritieshavedifferentinterpretationsofrequirementsforClinicalTrialApplications,GeneticModifiedOrganismlegislation,HospitalExemptionandGoodManufacturingPractice.Inexperienceandun-alignmentaremostmentioned.
![Page 9: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/9.jpg)
Capabilities and business model at the start have effect throughout ATMP development success.
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
ATMPdevelopmentismuchmorecomplexthantraditionaldrugdevelopment.Developerswhostartwithout(in-house)regulatoryandqualityexpertiseandbusinessgoalsmostlyaren’tabletocatchup,especiallyacademicspin-offandSMEs.
Arealisticbusinessmodeladdressesatleastthefollowingfactors:- Shortandlongtermdevelopmentgoals- Regulatoryandmarketaccessstrategy- Realisticreturnoninvestmentexpectationandprediction
Payers/HTAneedtojoinregulatorsininteractionstodecreasehighperceivedreimbursementcriteriaanduncertaintytomaintainpromiseofgrowingEUATMPmarket.
![Page 10: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/10.jpg)
Concluding: Escher-ATMP project
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
Europeaneffortsareverywellreceivedbydevelopers.Compared,nationalauthoritieshavenotmaturedandneedtobridgegapsbetweenEuropeandeachother.
• MoreharmonizationofCTA,GMOandGMPrequirementsbetweenmemberstatesisneededtofurtheradvanceEUATMPdevelopmentandcompetewithotherinternationalmarkets.
ATMPdevelopmentrequiresearlierplanningandspecialisedskillscomparedtotraditionaldrugdevelopment.StartingwitharealisticbusinessmodelandearlyregulatoryandHTAinvolvement.
EUATMPlandscapeisinearlystages,shownbythemajorityofcommercialdeveloperswhoareinearlyclinical(phaseI-II)productdevelopmentalstages.
![Page 11: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/11.jpg)
Concluding: Escher-ATMP project
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
Stakeholder specific recommendations
• LocalRegulators: NeedtobridgeknowledgegapbetweennationalandEuropeanregulatoryauthorities.Countryspecificrequirementsareamajorhurdlefordevelopers.
Payers/HTA: Needtocollaboratewithdevelopersandregulatorstoaddresslastmajorandmostlyunaddressedhurdle.ATMPHTAandreimbursementisinitsinfancy.
SMEs:EarlyonincludeGMPgradestandards,regulatoryandqualityknowledgeandbuildrealisticbusinessplan.Partnershipswithexperiencedpartytoacceleratedevelopmentandfunding.
• EuropeanRegulators:OntherighttracktoshapeEuropeanATMPlandscape,includelocalauthoritiesandpayers/HTAintheprocess.
Largecompanies:MosthadsamesteepATMPlearningcurveasSMEsbutmoreexperienceinnon-ATMPpharmaceuticaldevelopment.PartnerwithSMEstofillpipelineandaccelerateinnovation.
![Page 12: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/12.jpg)
Acknowledgements
EBE-EFPIAInitiative:Escher-ATMPProjectResultsByRensketenHam,MSc- DivisionofPharmacoepidemiologyandClinicalPharmacology- UtrechtUniversity
Dr.AndreBroekmansExecutiveDirector
Prof.Dr.OlafKlungelEpidemiologicalMethods
Dr.JarnoHoekmanAssistantProfessor
Dr.AnkeHövelsAssistantProfessor
Prof.Dr.MariekedeBruinRegulatoryScience,UnivofCopenhagenAssistantprofessor,UtrechtUniversity
ATMPworkinggroup
BarbaraFreischemExecutiveDirector
EstherChoiVCworkinggroup,BMS
![Page 13: EBE-EFPIA Initiative Escher-ATMP Project Results · Escher-ATMP Project EBE-EFPIA Initiative: Escher-ATMP Project Results By Renske ten Ham, MSc -Division of Pharmacoepidemiology](https://reader030.vdocuments.net/reader030/viewer/2022021715/5c110cae09d3f23b288b8842/html5/thumbnails/13.jpg)